MG
VIVO

Michael Gelband’s Meridian Bioscience Inc VIVO Stock Holding History

Michael Gelband’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-13,725
Closed -$257K – 2760
2020
Q4 		$257K Buy
+13,725
New +$256K ﹤0.01% 1616
2020
Q3 		– Sell
-50,071
Closed -$1.17M – 2369
2020
Q2 		$1.17M Buy
50,071
+35,872
+253% +$520K 0.03% 666
2020
Q1 		$119K Buy
+14,199
New +$120K 0.01% 866

Other funds holding VIVO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Michael Gelband's VIVO Position: Q1 2021 in Review

Michael Gelband sold out of Meridian Bioscience Inc (VIVO) in Q1 2021, closing a stake of 13,725 shares — an estimated $257K sold.

Michael Gelband first reported a position in VIVO in Q1 2020 and held it in 3 quarters. The position peaked at $1.17M in Q2 2020. 215 funds tracked by Wall St. Rank hold VIVO as of Q1 2021.

  • Michael Gelband reported no remaining Meridian Bioscience Inc position as of Q1 2021 after selling out during the quarter.
  • Michael Gelband sold 13,725 Meridian Bioscience Inc shares in Q1 2021, an estimated $257K.
  • Michael Gelband first reported a position in Meridian Bioscience Inc in Q1 2020 and held it in 3 quarters.
  • Michael Gelband's Meridian Bioscience Inc position peaked at $1.17M in Q2 2020.
  • 215 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2021.

Based on ExodusPoint Capital Management's 13F filing for Q1 2021, filed 17 May 2021.